
Dr. Reddy’s unveils generic of Solu-Medrol
The Hindu
HYDERABAD
Dr. Reddy’s Laboratories has unveiled Methylprednisolone Sodium Succinate for Injection, USP, its generic equivalent of Solu-Medrol, in the U.S. market.
The product, launched following the U.S. Food and Drug Administration (USFDA) approval, is indicated for various conditions, including arthritis, blood disorders, allergic reactions and certain cancers.
A trademark of Pharmacia & Upjohn Company LLC, Solu-Medrol brand and generic had U.S. sales of approximately $144 million MAT for the most recent 12 months ended in February 2022, Dr. Reddy’s said, citing IQVIA Health numbers.
The company said its Methylprednisolone Sodium Succinate for Injection, USP, is supplied in 40 mg/vial, 125 mg/vial single-dose vials each carton containing 25 vials; 500 mg and 1 gm multi-dose vial each carton containing 1 vial.

Insurance penetration and density are often misunderstood and do not reveal how many families are insured or whether they would be financially secure if the main earning member were to die. The real issue is not reach but adequacy, as households may have life insurance but not enough cover to replace lost income, leaving them financially vulnerable.












